Showing results (21-30 of 290) with videos related to
Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaJames Bean, Gregory J Riely, Marissa Balak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designJamie E Chaft, Geoffrey R Oxnard, Camelia S Sima, et al.JCO Precision Oncology|September 11, 2020
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center StudyAnita Chawla, Filip Janku, Jennifer J Wheler, et al.Lung Cancer (Amsterdam, Netherlands)|October 15, 2015
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progressionSai-Hong Ou, Jeffrey C Milliken, Michele C Azada, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic ProfilingAngel Qin, Adrienne Johnson, Jeffrey S Ross, et al.Cancer|December 25, 2018
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunitiesSherri Z Millis, Denis L Jardim, Lee Albacker, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Screening for germline EGFR T790M mutations through lung cancer genotypingGeoffrey R Oxnard, Vincent A Miller, Mark E Robson, et al.Cancer|April 22, 2005
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinibAntonio M P Omuro, Mark G Kris, Vincent A Miller, et al.Cancer|July 13, 2002
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin diseaseScott A Laurie, Mark G Kris, Carol S Portlock, et al.The Oncologist|September 19, 2020
Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT ExperienceSandy S Bohan, Jason K Sicklick, Shumei Kato, et al.Pageof 29